
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and up […]

